These Ukrainian women banded together after fleeing war. The U.S. may send them back.
'I was so worried because it was my first time' helping someone who's about to give birth, Julia said. She brought along a translator to ensure she and Viktoria could understand the English-speaking doctor. She stood by Viktoria's side, holding her hand and encouraging her through contractions. At the end of the night, Viktoria gave birth to a healthy baby girl, Emily.
Rushing to help other women is a common occurrence for Julia and the other community health workers at a nonprofit organization that helps refugee women and their families in and around Decatur, Georgia, acclimate to their new country.
In some cases, Julia's work week extends into the weekend, especially when one of her 40 clients or someone in their families needs translation assistance during a medical emergency, access to transportation or help understanding their insurance coverage.
'Sometimes, my job is 94 hours,' she said. 'Our work is very interesting, but it's so important to help these families.'
Since the early 2000s, the organization has served thousands of refugee and immigrant women by offering workshops, mental health services and networking opportunities. Its leaders asked The 19th to withhold the organization's name out of concern that using it might jeopardize the funding they receive from the federal government, given the uncertainty of the current political climate. Julia is also going by a name other than her own because she works at the organization, and The 19th agreed to withhold the last name for Viktoria and Vladislav because of their status.
The organization's clients are Afghans, who arrived in Georgia in 2021 after the Taliban took over their home country; Central Africans, who were pushed out in large part because of the volatile security situation in their country; and Ukrainians, who fled a war that has been raging for three years.
At the height of the COVID-19 pandemic, the organization bolstered its services to help women immigrants in metro Atlanta who needed to navigate conversations with health care providers. Community health workers had been an early part of the network, and the need for translation services and community connection led the organization to reintroduce the program, the organization's program coordinator of community health direction told The 19th.
Five years later, community health workers like Julia are the group's heart. The group serves more than 2,000 women immigrants and refugees each year and having representation is crucial to the work; 90 percent of the organization's staff are foreign-born.
The community health workers are now more necessary than ever. As the Trump administration implements more obstacles for refugees' pathways to citizenship and makes changes to the Temporary Protected Services program (TPS), which allows immigrants from certain countries to live in the United States legally for a period of time, many families, including Viktoria's, are left with fewer options and unsure of what's ahead.
Ukrainian refugees began arriving in the United States in 2022, when then-President Joe Biden created the Uniting for Ukraine program, granting Ukrainian citizens and their immediate families temporary stay in the country through what is known as humanitarian parole. In 2023, the Biden administration extended humanitarian parole to Cubans, Nicaraguans, Haitians and Venezuelans, both as a form of temporary relief from the unrest and instability in these countries and to curb the number of immigrants illegally entering the United States from Mexico.
Then came President Donald Trump, who, earlier this year, shortened the length of the protected status granted to these foreign nationals.
Nicaraguans now have protected status until July 5, Haitians have it until August 3 and Venezuelans until September 10, according to guidance from the U.S. Citizenship and Immigration Services (USCIS). What will happen to the program for immigrants from other countries, including Ukraine, is unclear.
The fates of as many as 532,000 people are in limbo, said Judith Delus Montgomery, an immigration lawyer from Clarkston, Georgia, a small city known as the 'Ellis Island of the South' due to its welcoming of more than 60,000 refugees since the 1970s. Her firm, Delus Montgomery, LLC, has served thousands of immigrant families in the metro Atlanta area for 13 years, and Montgomery herself has worked closely with the Haitian community.
Born in the Bahamas to Haitian immigrants, Montgomery said she became a U.S. citizen through her parents when she was a toddler. She said that her personal experience as an immigrant and naturalized citizen inspires her work.
Since the Trump administration announced it would shorten the protections for Haitian immigrants, which would have otherwise ended on February 3, 2026, Montgomery's days have been filled with anxious phone calls from clients. She has been working around the clock to help them find new ways to stay in the country legally and find other paths to citizenship.
'People are in an uproar,' she said. 'We have been inundated with phone calls.'
With the end of their TPS period quickly approaching, immigrants have only two other options to stay in the United States, Montgomery said. They can adjust their status through a family member who is already a citizen or, if that isn't an option, they can petition for asylum. But that is a tough road to follow. According to data collected by the Transactional Records Access Clearinghouse at Syracuse University, more than 3 million active cases are pending before the Immigration Court. Of those, more than 2 million are formal asylum applications from immigrants who are awaiting hearings and decisions on their cases. As reported by the National Immigration Forum, the average wait time for asylum applicants to be seen before USCIS is more than six years, and some wait much longer.
A lot of the people living in the United States under temporary protection don't have a home to go back to. 'Now you have all these folks here and don't have a pathway to citizenship [but] they absolutely can't go back. These folks are in a precarious situation,' Montgomery said.
That includes the Ukrainians affected by the Trump administration's impending changes to their protected status and who can no longer apply for temporary protected status or for the Uniting for Ukraine program. Before leaving office, Biden extended Ukrainians' stay in the United States until October 2026, but this is likely to change once the Trump administration completes its review of the parole programs, as outlined in the executive action called 'Securing Our Borders.'
Reuters estimates that as many as 240,000 Ukrainians have or will be affected by the changes. Julia and Viktoria are among them.
Julia's life is defined in periods: there's before the war and then there's everything that has happened since.
Before the war, Julia worked in sales and got some experience in the nonprofit space too, in a role where she helped organize games, workshops and training for college students.
She lived in an apartment complex in Lutsk with her parents, brother and nephews. When the war began, she assembled a go-bag — full of medicine, warm clothes, her passport and money — and kept it close at all times in case she had to evacuate.
Day in and day out, Julia traveled to and from work until curfew arrived in the evening. When Russian forces attacked their city, she and her family huddled together in basements, holding each other tightly as they waited for the blaring emergency alarms to end.
Julia had friends in the United States and they kept encouraging her to take advantage of the humanitarian program and relocate. It was a heartwrenching decision: Her parents didn't want to leave Ukraine and she didn't want to leave her parents.
But she did move eventually. Julia arrived in the United States in January 2023, alone. Her parents, brother and nephews stayed in Ukraine.
During an interview in mid-February at the organization where she works, Julia said that she, like many of her clients, was nervous and stressed about what she needed to do next. Because the Temporary Protected Status program isn't accepting any new applications, families like Julia's have been essentially broken up since none of those who stayed in Ukraine are able to legally enter the United States. And at least some of those who have relocated to the United States can't return home because their homes are now in Russian-occupied areas — Russian soldiers might be eating off their plates, wearing their clothes, sleeping in their bedrooms.
'Our cases are frozen,' Julia said.
Their lives are frozen.
Then there are couples like Viktoria and Vladislav. She is Ukranian. He is Russian. They were each living in their respective home country when they met on an online dating site for Christians eight years ago. After their pastors gave them the OK to meet in person, the two connected quickly and fell in love. Soon after, Viktoria moved to Russia and she and Vladislav got married.
After the war started, the couple and their first child, a girl, moved to Turkey, where their second child was born. Viktoria didn't feel safe as a Ukrainian living in Russia, especially after she shared her sentiments on the war on social media. The family lived in Turkey for 11 months. A close friend who lived in the United States told Viktoria and Vladislav about the humanitarian program. In 2023, the parents and their children moved to Dunwoody.
If the Trump administration forces them to leave, Viktoria and the couple's middle child aren't allowed to live in Russia, where Vladislav and the eldest daughter are from, because of their Ukrainian citizenship. In turn, Vladislav and the eldest daughter may not be able to live in Ukraine. Will the youngest child, the one whom Julia watched come into this world, be able to relocate to either country?
'You don't know what you need to do,' Vladislav said. Emily's path is less clear cut, he said, 'because she's an American citizen, and American governments don't recommend going to Ukraine because of the war or Russia because it isn't safe.'
There's also a bigger financial implication of Trump's approach to immigration. Across the country, agencies that help immigrants are struggling to keep their doors open or have laid off staff due to funding cuts.
The organization where Julia works has also been impacted.
While it isn't a refugee resettlement agency, the organization's program coordinator said its social adjustment and economic empowerment services are funded by federal grants that come through the Office of Refugee Resettlement and the Department of Health and Human Services. These grants, which account for almost half of the organization's annual funding, are at risk. If they're gone, cuts are all but inevitable.
These cuts would happen just as the changes to immigration policies under Trump have amplified the need for the types of services the organization offers. With resettlement agencies shutting their doors, the group has received an influx of new clients whose original case managers are no longer available.
As Julia and her fellow community health workers help more and more people, the program coordinator said she has tried to remind them of the importance of self-care. But that can be difficult to balance when it's not only more clients that they're seeing, but also clients facing more severe challenges.
In just two weeks, the program coordinator said, the organization had helped more than 100 families get utility assistance, an increase that reflects a surge in housing issues and the number of families the organization has provided services for since the Trump administration began making changes.
As the uncertainty lingers and changes begin to take effect, the program coordinator anticipates an increase in homelessness among the families the organization helps, more difficulty in finding work and exacerbated mental health struggles.
Those who had to leave their native countries and embraced the United States as their home are now realizing their new life isn't actually safe.
Amid the struggles, the community has banded together to lend a hand. The organization has made room for them by ramping up its volunteer program that delivers food to families. It's also accepting more donations and it has stepped up its outreach allies to help those who need legal assistance, the program coordinator said.
Julia remembers feeling lost when she first arrived in Atlanta. She missed her family and wanted to go back to Ukraine, but a friend encouraged her to wait a year before making any big decisions. In many ways, it's her work at the organization that has rooted her in the United States and kept her grounded in these times.
She was taking English as a Second Language courses at Georgia State University when a teacher asked if she'd be interested in connecting with other Ukrainian refugees in the community. She agreed and was hired after her first interview with the organization. Immersing herself in the world of clients — a world so much like her own — was a whirlwind experience, but Julia enjoys helping and connecting with others. As she likes to say, she didn't find the organization. It found her.
Julia said that as time has passed since Trump announced changes to the Temporary Protected Status program, some of her clients have been getting in contact with lawyers to see what their options might be. Faced with the possibility of uprooting their families and starting their lives over once again, many have been feeling depressed and overwhelmed.
Julia is also contemplating what might happen to her. In January, she applied to continue her Temporary Protected Status, but because cases like hers are paused, she hasn't heard any updates. Her original stay was set to end April 19.
Depending on what the Trump administration does next, she said, she might return to Ukraine to be with her family or continue her work in Atlanta.
In the meantime, it's the connection to her community that keeps her going. There's her friendship with Viktoria, whose family is one of the many that remind her that life in the United States can be beautiful and complicated all the same.
'Every person I've met has a deep story of fighting to survive, to help, to support,' she said. 'Sometimes life is very easy, but sometimes it's very complicated and heavy.'
She paused; looked at Viktoria and Vladislav, who were watching their second daughter as she played on the playground outside of the organization's office; and said, 'But this country supports us and I hope this country will continue to support us.'
The post These Ukrainian women banded together after fleeing war. The U.S. may send them back. appeared first on The 19th.
News that represents you, in your inbox every weekday. Subscribe to our free, daily newsletter.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd alone With the first global approval in TE NDMM, Sarclisa is now approved in the EU across all lines of therapy, regardless of transplant eligibility Paris, July 25, 2025. Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 19, 2025, the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant. 'We have been on a mission to accelerate Sarclisa's clinical development program with the hope to bring this important medicine to as many people as possible living with multiple myeloma,' said , Global Head of Oncology at Sanofi. 'Today's decision represents a prime example of those efforts, and most importantly, paves the way for Sarclisa to potentially become accessible to even more patients in the EU, regardless of transplant eligibility or line of therapy.' The approval is based on results from part one of the two-part, double-randomized, German-speaking Myeloma Multicenter Group (GMMG)-HD7 phase 3 study (clinical study identifier: NCT03617731), which was designed to independently assess the effects of Sarclisa during the induction and maintenance phases. Sarclisa-VRd demonstrated a deep and rapid response in transplant-eligible (TE) NDMM patients compared to VRd alone, reflected by a statistically significant minimal residual disease (MRD) negativity benefit at the end of the 18-week induction period, which was the primary endpoint of part one. These MRD results were supported by the final progression-free survival (PFS) analysis of part one (induction and transplant), which demonstrated a statistically significant and clinically meaningful improvement in PFS in patients treated with Sarclisa-VRd during induction, regardless of the maintenance therapy received. Additionally, the majority (53.1%) of patients receiving Sarclisa-VRd experienced continued MRD negativity (compared to 38% in the control arm), defined as MRD negativity persisting from post-induction to post-transplant, which was consistent with the prolonged PFS benefit. The results are part of the growing body of clinical evidence supporting the use of Sarclisa in the front-line setting and reinforce the potential of Sarclisa-VRd when used prior to transplant. Data from part two, the maintenance portion of the study, are forthcoming. With four approved indications globally, including two in the front-line setting, the approval further affirms Sarclisa as an established MM treatment option, reflecting Sanofi's ambition to address critical unmet needs in MM care and make a meaningful difference in treatment outcomes at every stage of the disease. About the GMMG-HD7 studyGMMG-HD7 is a pivotal, randomized, open-label, multicenter, two-part phase 3 study evaluating Sarclisa in combination with VRd, also referred to as RVd (lenalidomide, bortezomib, and dexamethasone), versus VRd induction followed by post-transplant re-randomization to Sarclisa plus lenalidomide versus lenalidomide maintenance alone in TE NDMM patients. The GMMG-initiated study is being conducted in close collaboration with Sanofi based on jointly defined research. Sanofi provided financial support to GMMG for this study. In December 2021, Sanofi and GMMG shared results from part one, which met the primary endpoint of MRD negativity after induction therapy and before transplant in NDMM patients. The study enrolled 662 patients with TE NDMM across 67 sites in Germany. In the first part of the study, all participants were equally randomized to receive three 42-day induction cycles of VRd in both arms of the study, while Sarclisa was added to only one study arm. After induction treatment, all patients received intensification therapy with autologous stem cell transplant. In the second part of the study, patients were re-randomized post-transplant to receive Sarclisa plus lenalidomide or lenalidomide alone as maintenance therapy. During part one of the study, Sarclisa was administered through an intravenous infusion at a dose of 10 mg/kg once weekly for the first four weeks of cycle one, then every other week for the rest of the induction period. The GMMG-HD7 protocol defined two primary endpoints: MRD negativity following induction therapy in the first part of the study, and PFS after the second randomization post-transplant in the second part, where Sarclisa was added to lenalidomide maintenance. The latter endpoint is expected to be available in due course. The key secondary endpoint for the first part of the study was PFS from first randomization. Additional secondary endpoints included rates of complete response after induction, and intensification, overall survival, and safety. MRD negativity was assessed by next-generation flow cytometry (sensitivity of 1x10-5) after induction. In the latest results, PFS for both arms, regardless of maintenance therapy, were measured from the first randomization. About SarclisaSarclisa (isatuximab) is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple lines of treatment for MM. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in the US and Japan in combination with pomalidomide and dexamethasone (Pd) for the treatment of patients with relapsed or refractory multiple myeloma (R/R MM) who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor. Additionally, Sarclisa is approved in the EU in combination with Pd for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor and have relapsed on the last therapy, and in China for patients who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, and China, Sarclisa is approved in combination with VRd as a front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study. Sarclisa is also approved in the EU in combination with VRd as an induction treatment for transplant-eligible NDMM patients, based on the GMMG-HD7 phase 3 study. In Japan, Sarclisa is approved in combination with VRd as a front-line treatment option regardless of transplant eligibility. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on Sarclisa clinical studies, please visit About the German-speaking Myeloma Multicenter Group GMMG is the largest study group focusing on MM in Germany, with headquarters based in Heidelberg. Within the last 20+ years, the GMMG study group has performed numerous studies including five randomized, multicenter phase 3 studies with 4,000 patients enrolled from about 90 participating and cotreating centers throughout Germany. The overall goal of GMMG is to generate improved therapies for myeloma patients through the development and testing of novel and personalized, genome- and signaling driven treatment strategies. The GMMG has set itself the goal of achieving further approvals for effective antibody-based drug combinations for the first-line treatment of myeloma patients, in which antibody-based treatment regimens have been integrated into seven GMMG study concepts (CONCEPT, DANTE, DADA, HD6, HD7, HD8, HD9 and HD10). About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press ReleaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd alone With the first global approval in TE NDMM, Sarclisa is now approved in the EU across all lines of therapy, regardless of transplant eligibility Paris, July 25, 2025. Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 19, 2025, the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant. 'We have been on a mission to accelerate Sarclisa's clinical development program with the hope to bring this important medicine to as many people as possible living with multiple myeloma,' said , Global Head of Oncology at Sanofi. 'Today's decision represents a prime example of those efforts, and most importantly, paves the way for Sarclisa to potentially become accessible to even more patients in the EU, regardless of transplant eligibility or line of therapy.' The approval is based on results from part one of the two-part, double-randomized, German-speaking Myeloma Multicenter Group (GMMG)-HD7 phase 3 study (clinical study identifier: NCT03617731), which was designed to independently assess the effects of Sarclisa during the induction and maintenance phases. Sarclisa-VRd demonstrated a deep and rapid response in transplant-eligible (TE) NDMM patients compared to VRd alone, reflected by a statistically significant minimal residual disease (MRD) negativity benefit at the end of the 18-week induction period, which was the primary endpoint of part one. These MRD results were supported by the final progression-free survival (PFS) analysis of part one (induction and transplant), which demonstrated a statistically significant and clinically meaningful improvement in PFS in patients treated with Sarclisa-VRd during induction, regardless of the maintenance therapy received. Additionally, the majority (53.1%) of patients receiving Sarclisa-VRd experienced continued MRD negativity (compared to 38% in the control arm), defined as MRD negativity persisting from post-induction to post-transplant, which was consistent with the prolonged PFS benefit. The results are part of the growing body of clinical evidence supporting the use of Sarclisa in the front-line setting and reinforce the potential of Sarclisa-VRd when used prior to transplant. Data from part two, the maintenance portion of the study, are forthcoming. With four approved indications globally, including two in the front-line setting, the approval further affirms Sarclisa as an established MM treatment option, reflecting Sanofi's ambition to address critical unmet needs in MM care and make a meaningful difference in treatment outcomes at every stage of the disease. About the GMMG-HD7 studyGMMG-HD7 is a pivotal, randomized, open-label, multicenter, two-part phase 3 study evaluating Sarclisa in combination with VRd, also referred to as RVd (lenalidomide, bortezomib, and dexamethasone), versus VRd induction followed by post-transplant re-randomization to Sarclisa plus lenalidomide versus lenalidomide maintenance alone in TE NDMM patients. The GMMG-initiated study is being conducted in close collaboration with Sanofi based on jointly defined research. Sanofi provided financial support to GMMG for this study. In December 2021, Sanofi and GMMG shared results from part one, which met the primary endpoint of MRD negativity after induction therapy and before transplant in NDMM patients. The study enrolled 662 patients with TE NDMM across 67 sites in Germany. In the first part of the study, all participants were equally randomized to receive three 42-day induction cycles of VRd in both arms of the study, while Sarclisa was added to only one study arm. After induction treatment, all patients received intensification therapy with autologous stem cell transplant. In the second part of the study, patients were re-randomized post-transplant to receive Sarclisa plus lenalidomide or lenalidomide alone as maintenance therapy. During part one of the study, Sarclisa was administered through an intravenous infusion at a dose of 10 mg/kg once weekly for the first four weeks of cycle one, then every other week for the rest of the induction period. The GMMG-HD7 protocol defined two primary endpoints: MRD negativity following induction therapy in the first part of the study, and PFS after the second randomization post-transplant in the second part, where Sarclisa was added to lenalidomide maintenance. The latter endpoint is expected to be available in due course. The key secondary endpoint for the first part of the study was PFS from first randomization. Additional secondary endpoints included rates of complete response after induction, and intensification, overall survival, and safety. MRD negativity was assessed by next-generation flow cytometry (sensitivity of 1x10-5) after induction. In the latest results, PFS for both arms, regardless of maintenance therapy, were measured from the first randomization. About SarclisaSarclisa (isatuximab) is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple lines of treatment for MM. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in the US and Japan in combination with pomalidomide and dexamethasone (Pd) for the treatment of patients with relapsed or refractory multiple myeloma (R/R MM) who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor. Additionally, Sarclisa is approved in the EU in combination with Pd for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor and have relapsed on the last therapy, and in China for patients who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, and China, Sarclisa is approved in combination with VRd as a front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study. Sarclisa is also approved in the EU in combination with VRd as an induction treatment for transplant-eligible NDMM patients, based on the GMMG-HD7 phase 3 study. In Japan, Sarclisa is approved in combination with VRd as a front-line treatment option regardless of transplant eligibility. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on Sarclisa clinical studies, please visit About the German-speaking Myeloma Multicenter Group GMMG is the largest study group focusing on MM in Germany, with headquarters based in Heidelberg. Within the last 20+ years, the GMMG study group has performed numerous studies including five randomized, multicenter phase 3 studies with 4,000 patients enrolled from about 90 participating and cotreating centers throughout Germany. The overall goal of GMMG is to generate improved therapies for myeloma patients through the development and testing of novel and personalized, genome- and signaling driven treatment strategies. The GMMG has set itself the goal of achieving further approvals for effective antibody-based drug combinations for the first-line treatment of myeloma patients, in which antibody-based treatment regimens have been integrated into seven GMMG study concepts (CONCEPT, DANTE, DADA, HD6, HD7, HD8, HD9 and HD10). About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release
Yahoo
a day ago
- Yahoo
Artisight introduces voice-activated interpreters into hospital platform
Artisight has introduced voice-activated medical interpreters on its Smart Hospital Platform, enabling clinicians to communicate with patients in over 240 languages. This innovation, developed in collaboration with LanguageLine Solutions, provides 24/7 access to medical interpreters, including American Sign Language, and is compatible with any hospital's existing translation services. Clinicians will now be able to access interpreters during patient encounters with a verbal cue. An interpreter appears on the Artisight-connected TV when providers say "OK Artisight – Spanish Interpreter." This feature addresses the critical need for immediate medical interpretation in the US, where one in five residents speak a language other than English at home. Artisight CEO and co-founder Dr Andrew Gostine said: 'For the first time, clinicians can bring an interpreter in the room with a voice command. This is another example of how we're building the infrastructure to bring advanced technology into hospitals, eliminating friction for clinicians and patients at the bedside.' Studies have indicated that patients with Limited English Proficiency (LEP) are less likely to receive preventive care and more likely to suffer adverse health outcomes. The availability of on-demand interpretation aims to bridge language and cultural divides, enhancing diagnoses, treatment adherence, and overall medical outcomes. In addition, language access significantly improves staff efficiency. The Voice-Activated Interpreter service is now accessible at several hospitals using Artisight's Smart Hospital Platform. Remote caregivers can also use LanguageLine's audio and video interpretation services, ensuring language support is available irrespective of location. Artisight's platform has already been successful in reducing nurses' administrative workload by over 30 minutes per shift. The introduction of on-demand interpreters in patient rooms further streamlines clinicians' tasks. This latest feature supports Artisight's mission to revolutionise healthcare through advanced AI technologies, including NVIDIA's TensortRT, Triton, and Jetson NX GPUs. "Artisight introduces voice-activated interpreters into hospital platform" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.